Ketorolac Tromethamine Injection
NDC Package 0641-6041-25
Package Information
Ketorolac Tromethamine injection is ketorolac is used for the short-term treatment of moderate to severe pain. This formulation utilizes a injection delivery system. Marketed by Hikma Pharmaceuticals Usa Inc., this product is identified by NDC 0641-6041 and is authorized under FDA application ANDA075772.
Identification & Billing
- RxCUI: 1665459 - ketorolac tromethamine 60 MG in 2 ML Injection
- RxCUI: 1665459 - 2 ML ketorolac tromethamine 30 MG/ML Injection
- RxCUI: 1665459 - ketorolac tromethamine 60 MG per 2 ML Injection
- RxCUI: 1665461 - ketorolac tromethamine 30 MG in 1 ML Injection
- RxCUI: 1665461 - 1 ML ketorolac tromethamine 30 MG/ML Injection
Clinical Specifications
- Intramuscular - Administration within a muscle.
- Intravenous - Administration within or into a vein or veins.
Regulatory & Marketing
Hierarchy Structure
- 0641 - Hikma Pharmaceuticals Usa Inc.
- 0641-6041 - Ketorolac Tromethamine
- 0641-6041-25 - 25 VIAL in 1 CARTON / 1 mL in 1 VIAL (0641-6041-01)
- 0641-6041 - Ketorolac Tromethamine
The NDC Directory contains ONLY information on final marketed drugs submitted to FDA electronically by labelers. A labeler might be a manufacturer, re-packager or re-labeler. The product information included in the NDC directory does not indicate that FDA has verified the information provided by the product labeler. Assigned NDC numbers are not in any way an indication of FDA approval of the product.
* Please review the full disclaimer at the bottom of this page.
Frequently Asked Questions
What is the distribution configuration for this product package?
The code 0641-6041-25 identifies a specific commercial package of 25 vial in 1 carton / 1 ml in 1 vial (0641-6041-01) of Ketorolac Tromethamine, a human prescription drug labeled by Hikma Pharmaceuticals Usa Inc.. This injection is formulated for intramuscular; intravenous use and contains ketorolac tromethamine as the active substance.
Is this product currently listed with the FDA?
Yes, this product is active and verified within the NDC Directory. It was introduced to the market by Hikma Pharmaceuticals Usa Inc. on July 21, 2004. The current certification is valid through December 31, 2026.
What are the primary indications for this medication?
Ketorolac is used for the short-term treatment of moderate to severe pain. It is usually used before or after medical procedures or after surgery. Reducing pain helps you recover more comfortably so that you can return to your normal daily activities. This medication is a nonsteroidal anti-inflammatory drug (NSAID). It works by blocking your body's production of certain natural substances that cause inflammation. This effect helps to decrease swelling, pain, or fever. Ketorolac should not be used for mild or long-term painful conditions (such as arthritis).
How is this Hikma Pharmaceuticals Usa Inc. product billed for insurance claims?
For medical billing and reimbursement, this package follows the 11-digit CMS format: 00641604125. Quantities are measured in per "ml or milliliter", products billed per milliliter are usually products measured by liquid volume.. The table below illustrates the segment conversion from the 10-digit labeler code to the 11-digit provider format.
11-Digit Code Conversion
Billing payers usually require a 5-4-2 segment configuration. Below is the conversion from the 10-digit package format to the 11-digit billing format:
Note: The zero is added to the Labeler segment to maintain the 5-4-2 structure.